VGX-3400: Phase I data

An open-label, dose-escalation, U.S. and Korean Phase I trial in 60 healthy volunteers showed that 2 intramuscular injections of 0.2, 0.67 or 2 mg VGX-3400X delivered by Inovio's CELLECTRA electropora...